{"id":972543,"date":"2026-06-16T08:20:13","date_gmt":"2026-06-16T12:20:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/"},"modified":"2026-06-16T08:20:13","modified_gmt":"2026-06-16T12:20:13","slug":"lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/","title":{"rendered":"Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SARASOTA, Fla.<\/span>, June 16, 2026<\/span> \/PRNewswire\/ — Lakewood-Amedex Biotherapeutics Inc.<\/a>, (NASDAQ: LABT, the “Company”), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin\u00ae<\/sup> class, today announced that Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research, will present at the Life Sciences Virtual Investor Forum on June 25, 2026.<\/p>\n

\n

\n \"Lakewood-Amedex\"\n <\/p>\n<\/p><\/div>\n

\n Presentation Details:<\/b>\n <\/p>\n

\n\n\n\n\n
\n

\n Event:<\/span>\n <\/p>\n<\/td>\n

\n

\n Life Sciences Virtual Investor Forum<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Date\/Time<\/span>\n <\/p>\n<\/td>\n

\n

\n June 25, 2026, at 11:30, AM EDT<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Website<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Registration Link<\/a>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

“We look forward to presenting Lakewood-Amedex Biotherapeutics’ growth strategy and the ground-breaking potential of our lead candidate, Nu-3, a topical gel being developed for the treatment of infected diabetic foot ulcers (iDFU),” said Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research and Development. “Mild iDFU impacts millions of people worldwide, potentially leading to serious infections and ultimately amputations. As we advance Nu-3 into Phase 2 clinical trials, we believe there is an opportunity to generate substantial value given the drug’s unique mechanism of action and its potential to address a large and underserved patient population.”<\/p>\n

\n About Lakewood-Amedex Biotherapeutics Inc.
<\/b>Lakewood-Amedex Biotherapeutics Inc. (<\/span>NASDAQ: <\/span>LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum <\/span>antimicrobials \u2013 the <\/span>Bisphosphocin\u00ae class – to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including <\/span>MRSA, <\/span>VRE, and others. For more information, please visit <\/span>https:\/\/lakewoodamedex.com<\/a>.<\/span><\/p>\n

\n Forward-Looking Statements
<\/b>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.’s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin\u00ae platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results may not be predictive of future results; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the company’s SEC filings, including under “Risk Factors.” Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update them except as required by law.<\/p>\n

\n
\n Contact<\/u>
\n <\/b>\n <\/p>\n

Investor Relations
Tiberend Strategic Advisors, Inc<\/a>.
David Irish
(231) 632-0002
dirish@tiberend.com<\/a><\/p>\n

Media Relations
Tiberend Strategic Advisors, Inc<\/a>.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum-302800916.html<\/a><\/p>\n

SOURCE Lakewood-Amedex Biotherapeutics Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SARASOTA, Fla., June 16, 2026 \/PRNewswire\/ — Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the “Company”), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin\u00ae class, today announced that Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research, will present at the Life Sciences Virtual Investor Forum on June 25, 2026. Presentation Details: Event: Life Sciences Virtual Investor Forum Date\/Time June 25, 2026, at 11:30, AM EDT Website Registration Link “We look forward to presenting Lakewood-Amedex Biotherapeutics’ growth strategy and the ground-breaking potential of our lead candidate, Nu-3, a topical gel being developed for the treatment of infected diabetic foot ulcers (iDFU),” said Kelvin Cooper, Ph.D., Chief … <\/p>\n

Continue reading “Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-972543","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SARASOTA, Fla., June 16, 2026 \/PRNewswire\/ — Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the “Company”), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin\u00ae class, today announced that Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research, will present at the Life Sciences Virtual Investor Forum on June 25, 2026. Presentation Details: Event: Life Sciences Virtual Investor Forum Date\/Time June 25, 2026, at 11:30, AM EDT Website Registration Link “We look forward to presenting Lakewood-Amedex Biotherapeutics’ growth strategy and the ground-breaking potential of our lead candidate, Nu-3, a topical gel being developed for the treatment of infected diabetic foot ulcers (iDFU),” said Kelvin Cooper, Ph.D., Chief … Continue reading "Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T12:20:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS606836\/Lakewood-Amedex_v2_Logo.jpg?id=OA2717240\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum\",\"datePublished\":\"2026-06-16T12:20:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\\\/\"},\"wordCount\":448,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS606836\\\/Lakewood-Amedex_v2_Logo.jpg?id=OA2717240\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\\\/\",\"name\":\"Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS606836\\\/Lakewood-Amedex_v2_Logo.jpg?id=OA2717240\",\"datePublished\":\"2026-06-16T12:20:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS606836\\\/Lakewood-Amedex_v2_Logo.jpg?id=OA2717240\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS606836\\\/Lakewood-Amedex_v2_Logo.jpg?id=OA2717240\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/","og_locale":"en_US","og_type":"article","og_title":"Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum - Market Newsdesk","og_description":"PR Newswire SARASOTA, Fla., June 16, 2026 \/PRNewswire\/ — Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the “Company”), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin\u00ae class, today announced that Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research, will present at the Life Sciences Virtual Investor Forum on June 25, 2026. Presentation Details: Event: Life Sciences Virtual Investor Forum Date\/Time June 25, 2026, at 11:30, AM EDT Website Registration Link “We look forward to presenting Lakewood-Amedex Biotherapeutics’ growth strategy and the ground-breaking potential of our lead candidate, Nu-3, a topical gel being developed for the treatment of infected diabetic foot ulcers (iDFU),” said Kelvin Cooper, Ph.D., Chief … Continue reading \"Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-16T12:20:13+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS606836\/Lakewood-Amedex_v2_Logo.jpg?id=OA2717240","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum","datePublished":"2026-06-16T12:20:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/"},"wordCount":448,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS606836\/Lakewood-Amedex_v2_Logo.jpg?id=OA2717240","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/","name":"Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS606836\/Lakewood-Amedex_v2_Logo.jpg?id=OA2717240","datePublished":"2026-06-16T12:20:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS606836\/Lakewood-Amedex_v2_Logo.jpg?id=OA2717240","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS606836\/Lakewood-Amedex_v2_Logo.jpg?id=OA2717240"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=972543"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972543\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=972543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=972543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=972543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}